搜尋結果
2022年4月19日 · A study by the University of Hong Kong has for the first time compared the effectiveness of China’s Sinovac vaccine with the mRNA vaccine developed by BioNTech against the Omicron variant of...
2021年2月19日 · 早前香港醫院藥劑師學會就比較了科興 (Sinovac)疫苗、復星 (Fosun) / BioNTech及阿斯利康 (AstraZeneca)於副作用、產地、有效率等方面的分別，即睇三大供港疫苗的比較分析詳情。 科興 (Sinovac)疫苗. 疫苗生產地為中國北京，種類屬滅活疫苗，劑型為預充式注射器，每支注射器可提供一個劑量。 臨床研究中常見副作用. 點擊圖片放大. 第一針及第二針發燒率. 18至59歲：第一針：2.1%；第二針：1.4% 效能. 50.66%-62.3%。 調配方法. 不用稀釋或解凍. 運送方法. 運送過程需維持 2°C 至 8 °C. 接種中心地址. 點擊圖片放大. 復星 (Fosun) / BioNTech.
2021年6月24日 · Updated: January 3rd, 2021. Written by Dr David Owens. Answer: Of the two available vaccines in Hong Kong BioNTech is the most effective. Both the vaccines available in Hong Kong are very good at preventing death and serious illness against the original SARS-COV-2 virus.
2021年7月29日 · Against the original virus BioNTech was 95% effective compared to 50.7% for Sinovac. BioNTech drops to 88% against Delta. Recent studies suggest that Sinovac is significantly less effective against Delta and has no neutralizing immunity against Omicron
2021年2月25日 · 國產科興疫苗首批100萬劑疫苗已於日前運抵本港，而首批德國生產的BioNTech疫苗「復必泰」疫苗原定今（25日）抵港，惟政府證實因出口程序未完成，未能預期運到香港。 新冠疫苗接種計劃將於明日起展開。 中大香港亞太研究所城市與區域發展研究中心就疫苗在同步接種或延遲接種的情況下，評估比較本港預購3款疫苗的平均保護率，即分別有科興疫苗、阿斯利康/牛津疫苗、BioNTech/復星「復必泰」疫苗。 閱讀全文. 27065次閱讀. 新冠疫苗 新冠病毒抗體測試. 有研究就疫苗在同步接種或延遲接種的情況下，評估比較本港預購3款疫苗的平均保護率，即分別有科興疫苗、阿斯利康/牛津疫苗、BioNTech/復星「復必泰」疫苗。
其他人也問了
How effective is Sinovac vs biontech?
How effective is Sinovac against Omicron?
Do you need a third dose of Sinovac in Hong Kong?
2022年6月10日 · The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has issued updated interim policy recommendations for the use of the Sinovac-CoronaVac vaccine against COVID-19. This article provides a summary of those interim recommendations; you may access the full guidance document here .
2021年6月19日 · Victor Ting. + FOLLOW. Published: 8:00am, 19 Jun 2021. Why you can trust SCMP. A major Hong Kong study has found “substantially higher” levels of antibodies in people vaccinated against Covid-19...
